Trials / Completed
CompletedNCT00861042
An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the trial is to assess the tolerability and safety of long-term SPM 927 administration in subjects with diabetic neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPM927/Lacosamide | SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2004-12-01
- Completion
- 2005-03-01
- First posted
- 2009-03-13
- Last updated
- 2024-01-29
Source: ClinicalTrials.gov record NCT00861042. Inclusion in this directory is not an endorsement.